Rubin DT, Dotan I, DuVall A, Bouhnik Y, et al. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol 2021 Nov 16. pii: S2468-1253(21)00338.
PMID: 34798036